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Microtubules (MTs) are a highly successful target for anticancer therapy. MT-stabilizing agents (MSAs) bind
to MTs, promoting their polymerization, blocking mitosis, and causing cell death. There are currently four
clinically important MSAs, with many others in preclinical and clinical development. MTs have three binding
sites for these compounds; however, the exact locations and drug-protein interactions of these sites are still
controversial. This review will describe the possible binding sites, the compounds that bind to them, and the
effect of this binding onMT function. The binding site of an MSA on tubulin is important for characterizing the
compound as an anticancer agent and provides insight not only into possible synergistic interactions with
other compounds but also on the MSA ‘‘pharmacophore.’’ This information can aid in the design of novel
MSAs with improved properties.Microtubules
Microtubules (MTs) are essential in all eukaryotic cells as key
components of the cytoskeleton. They are critical for a number
of cellular processes, most importantly, cell division and mitosis.
MTs are characterized by their dynamic behavior, constantly
switching between periods of elongation and shrinkage, driven
by the energy obtained from guanosine-5’-triphosphate (GTP)
hydrolysis. Upon polymerization, tubulin assumes a straight
conformation, and potential energy is stored within the MT
lattice. Depolymerization releases this energy, and the released
dimers resume a curved conformation (Nogales et al., 2003).
The tubulin heterodimer is made up of an a and a b subunit,
arranged in a polar head-to-tail fashion, and these heterodimers
assemble into protofilaments that arrange in a parallel manner to
form the MT. Each subunit contains a nucleotide binding site.
The a subunit has a stable nonexchangeable nucleotide binding
site (N-site) that binds GTP. The b subunit has an exchangeable
nucleotide site (E-site) that binds GTP or GDP. Bound GTP at the
E-site is hydrolyzed to GDP soon after polymerization. Assembly
is favored whenGTP is bound to the E-site; whereas, GDP favors
disassembly. A polymerizing MT therefore has a ‘‘GTP cap’’ on
its growing end that stabilizes the straight conformation of the
MT lattice (Akhmanova and Steinmetz, 2008). Hydrolysis of
GTP to GDP is not required for the assembly of the MT but is
required for its dynamic instability (Jordan and Wilson, 2004).
GTP-bound dimers are able to form protofilaments; whereas,
GDP-bound dimers are inactive, prone to disassembly, and form
double rings in the presence of Mg2+. Although it was originally
thought that GTP-bound dimers were straight (allosteric model),
it has now been shown in biochemical and structural studies that
this is not the case. The lattice model predicts that unassembled
tubulin is in a naturally curved state, regardless of the bound
nucleotide, and that on polymerization, it takes on a straight or
activated state. The g-phosphate of GTP only lowers the free
energy between the two different nucleotide dimer states. The
dimers only differ in their flexibility for adopting a straight con-
formation that is driven by the lateral and longitudinal contacts
occurring upon polymer assembly (Buey et al., 2006). This
implies that all tubulin dimers, irrespective of nucleotide bound,Chemistry & Bioare in a ‘‘MT incompatible’’ state, or an inactive curved state, and
are driven to the straight conformation as a consequence of
lateral contacts made during MT assembly. This has been
confirmed by crystallography (Gigant et al., 2000; Nawrotek
et al., 2011).
Microtubule-Targeting Drugs
Drugs that target the MT can be classified into two main groups
based on their mechanism of action. MT-destabilizing agents
(MDAs) promote depolymerization and prevent polymerization
of tubulin, and MT-stabilizing agents (MSAs) promote polymeri-
zation of tubulin and stabilize the polymer, preventing depoly-
merization. These compounds are able to induce the formation
of tubulin polymers even when GDP is bound in the E-site;
whereas, normally under these conditions, tubulin does not
assemble into MTs. Although many MT-associated proteins
(MAPs) are known to be MT stabilizers, nonendogenous MSAs
tend to bind more tightly, inhibiting the natural activity of tubulin
by promoting near irreversible assembly (Amos, 2011). The exact
mechanism of mitotic arrest and consequent apoptosis induced
by an MSA is still not fully understood. It is however widely
accepted that their antimitotic action occurs through interfer-
ence with the spindle dynamics within the cell. Affected cells
fail to pass mitotic checkpoints and arrest at the G2/M phase
of the cell cycle. G2/M block is the hallmark of MTAs. Cells
blocked in G2/M subsequently undergo cell death (Jordan and
Wilson, 2004). Both MSAs and MDAs have proven successful
in the clinic in treating a number of different cancers. At high
concentrations, these drugs have opposite effects on polymer
mass; however, at low concentrations, these drugs have a similar
effect, that of inhibiting the dynamic instability of MTs (Nogales,
2000; Jordan andWilson, 2004). MTs are also required for endo-
thelial cell migration, and thus some MT-targeting agents are
able to inhibit angiogenesis as well as mitosis, inhibiting vascu-
larization of tumors (Jordan and Wilson, 2004).
The majority of MSAs are natural products or synthetic deriv-
atives of natural products. These compounds have most likely
evolved as broad-spectrum toxins to target eukaryotic tubulin
in predators and/or prey. In addition to cancer, some MSAslogy 20, March 21, 2013 ª2013 Elsevier Ltd All rights reserved 301
Figure 1. Structures of Microtubule-Stabilizing Agents
Stabilizing agents referred to in the text have been numbered using standard
IUPAC numbering.
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et al., 2009; Brunden et al., 2009). The first agent to be identified
as an MSA was paclitaxel (Taxol) (PTX) (Schiff et al., 1979). PTX
received FDA approval in 1992 and has been clinically used
against cancer since 1993, along with one of its semisynthetic
analogs docetaxel (Taxotere) (DTX), which has been clinically
available since 1996. These drugs are used to treat solid tumor
malignancies such as breast cancer, ovarian cancer, nonsmall
cell lung cancer, gastroesophageal cancer, germ cell tumors,
and cancers of the head and neck. The taxanes can be used in
neoadjuvant, adjuvant, and metastatic settings or in synergistic
combinations with other drugs (Jordan and Wilson, 2004).
More recently, cabazitaxel (Jevtana), another semisynthetic
taxane, has been FDA-approved (Galsky et al., 2010). Cabazi-
taxel has poor affinity for the P-glycoprotein drug efflux pump302 Chemistry & Biology 20, March 21, 2013 ª2013 Elsevier Ltd All rthat is involved in multidrug resistance and is effective in DTX-
resistant cancers. It is currently used in the clinic to treat
hormone-refractory metastatic prostate cancer. The epothilones
(EPOs) are macrolide antibiotics, and like the taxanes, bind to
and stabilize MTs (Bollag et al., 1995). The EPOs are considered
easier to produce than the taxanes with one synthetic derivative
currently used in the clinic: aza-EPOB (Ixempra) to treat meta-
static breast cancer. A number of EPOs are currently in clinical
development for different tumor types. New generation EPOs
are able to penetrate the blood-brain barrier, giving potential
for treatment of glioblastoma (Dumontet and Jordan, 2010).
Other MSAs at various stages of development, preclinical and
clinical, (reviewed by Amos, 2011) include discodermolide
(DSC), the sarcodictyins, eleutherobin, the laulimalides (LAUs),
the covalent binder cyclostreptin (CYC), the pelorusides
(PELs), dictyostatin, ceratamines (Manzo et al., 2003), and the
covalent binder zampanolide (ZMP) and its related enantiomer
dactylolide (DAC) (Figure 1). DSC entered a phase I clinical trial,
but the trial was discontinued due to significant pulmonary
toxicity (Dumontet and Jordan, 2010). In preclinical tests in
mice, despite showing promising results in cell-based and
pharmacokinetic studies, LAU proved ineffective in preventing
cancer xenograft growth and also presented with significant
systemic toxicity and mortality (Liu et al., 2007). PEL has shown
good efficacy in preclinical trials in mice. Three lung cancer
xenograft studies in mice were carried out comparing PEL
to PTX and DTX. Overall, PEL showed superior tumor growth
inhibition, including some actual tumor regression, and it was
better tolerated than the taxanes (Meyer et al., 2006). Given
these initial encouraging results, further preclinical development
of PEL was considered, but because a large-scale synthetic
program has not been possible, no clinical trials have yet been
entered into.
Recognizing the importance of MTs as a drug target, this
review will provide a description of the possible small molecule
binding sites on MTs, overview the different compounds
that bind to them, and discuss the effects of this binding on
MT function.
Microtubule-Stabilizing Agent Binding Sites
There are currently two well-known binding sites for MSAs on
the MT—the well-characterized luminal taxoid site and the less
well-characterized LAU/PEL site. There is also an external pore
type I site proposed that is associated with the taxoid site.
Thus, MSAs can be divided into two groups depending on the
site on the MT where they bind. The larger group includes PTX
and its biomimetics. These compounds bind to a site on the
luminal surface of b-tubulin in the MT, the taxoid site (Nogales
et al., 1998) and also may interact with the pore type I site
(Dı´az et al., 2003, 2005; Barasoain et al., 2010). Binding to the
pore type I site on its own can cause MT stabilization, leading
to cytotoxicity (Barasoain et al., 2010). Currently, all drugs
that bind the taxoid site bind with 1:1 stoichiometry: one MSA
molecule per heterodimer; thus, binding at these two sites
must be mutually exclusive (Dı´az and Andreu, 1993; Nogales
et al., 1995). The second group of binding agents consists of
LAU and PEL that target a not yet fully characterized binding
site. This site was originally shown, however, to be biochemically
distinct from the taxoid site (Pryor et al., 2002; Gaitanos et al.,ights reserved
Figure 2. Sequence and Secondary Structure of b-Tubulin
Alpha helices are shown in pink, b sheets in blue, and joining loops in yellow. TheM-loop is shown in purple and the S9-S10 loop in green. All segments are labeled
and defined as in Lo¨we et al. (2001), protein data bank entry 1JFF.
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this site on both the a- and b-tubulin subunits, but most recent
studies support an external b-tubulin site (see below).
The Taxoid Binding Site
The PTX binding site was first described 20 years ago by direct
photoaffinity-labeling to be on the b-tubulin subunit (Rao et al.,
1992), launching an active area of structural biology research.
Over the years, the view of the PTX binding site has been
gradually refined from an initial 6.5 A˚ model (Nogales et al.,
1995) to 3.5 A˚, to provide critical insights into this region (Nogales
et al., 1998, 1999; Lo¨we et al., 2001; Snyder et al., 2001; Li et al.,
2002). The early structural work confirmed that PTX binds with
1:1 stoichiometry and affects interactions between protofila-
ments. PTX was observed to bind in the intermediate domain,
occupying a site on the luminal face of b-tubulin where eight
extra residues are found in a-tubulin. The main interactions of
the compound involve the taxane ring. The majority of known
MSAs bind to the taxoid site and reversibly compete with PTX
for binding.
In this review, we explore the key structural features that form
the molecular basis for PTX /MT binding. We use the residue
numbering based on the structure alignment between a and
b subunits (Lo¨we et al., 2001) (1JFF in the Protein Data Bank);
therefore, the numbering of specific residues may differ by two
when referring to some of the original cited articles. Residues
361–368 (in the S9-S10 loop) are missing in the b-sequence
because the a subunit has an extra eight residues in this region.
Thus, the b-sequence numbering proceeds from b360 straight to
b369 (Figure 2).
The PTX binding pocket is located at the luminal site in
b-tubulin and is made up of the S9-S10 loop and parts of helices
H1, H6 and H7 (the core helix of the b subunit), and S7 (Figure 2).
The taxane ring of bound PTX sits on the N-terminal side of the
MT-loop (M-loop, connecting S7 to H9) that protrudes from the
protofilament and is an important secondary structure for stabi-
lization of the MT. Protofilaments are connected primarily by
interprotofilament interactions between the M-loops, H10-S2
loops, and the H2-S3 loops in adjacent protofilaments (Nogales
et al., 1998, 1999; Sui and Downing, 2010) where the most
important interaction is with the H10-S2 loop of the adjacent pro-
tofilament. PTX binding strengthens this contact by pushing theChemistry & BioM-loop out toward the neighboring protofilament, resulting in
more favorable contacts between adjacent protofilaments.
This interaction is crucial for stabilization by PTX and its
biomimetics because it increases the lateral protofilament inter-
actions (Nogales et al., 1995, 1998, 1999; Li et al., 2002; Sui and
Downing, 2010). The luminal site in b-tubulin has PTX facing the
inside of the MT, with the equivalent area in the a subunit being
occupied by eight extra amino acids (within the S9-S10 loop)
(Nogales et al., 1998; Amos and Lo¨we, 1999). The extra residues
in a-tubulin have a stabilizing effect on the M-loop, and it is
thought that PTX and other taxoid site compounds may mimic
this effect in the b subunit (Nogales et al., 1999; Lo¨we et al.,
2001). This has recently been confirmed by X-ray crystallography
(Prota et al., 2013).
The taxoid binding pocket lies in a ‘‘deep hydrophobic cleft’’
where three hydrogen bonds (H-bonds) and multiple hydro-
phobic contacts are made between PTX and tubulin (Snyder
et al., 2001). A considerable number of amino acid residues
have direct contacts with PTX when it is bound to tubulin (see
Figure 1 for carbon numbering of PTX, Figure 3 for the interaction
maps, and Table 1 for details about specific residues). In brief,
the view of PTX binding that emerged from early studies was
that PTX binds the b subunit in its second globular domain on
the opposite side of the core helix from where the E-site is
located and faces the inside of the MT (Amos and Lo¨we,
1999). Photoaffinity labeling identified amino acids within the
b subunit that were important in the binding of PTX (Rao et al.,
1994, 1995), and Arg284, a residue that is also mutated in
some PTX-resistant cells, was later identified as important for
the binding (Rao et al., 1999). Overall, the resolution of these
structures, however, was not good enough to completely
characterize PTX in its bound conformation, and the fact that
the information was based on zinc-stabilized sheets rather
than functional MTs meant that the interactions in vivo could
differ to some extent. In 2001, Snyder and colleagues used
computer docking based on crystallographic density analysis
to construct amodel of PTX in its bioactive conformation (Snyder
et al., 2001). This model confirmed that the taxoid binding site
was located within a deep hydrophobic cleft and involved three
potential H-bonds and a number of hydrophobic interactions,
supporting the previous research.logy 20, March 21, 2013 ª2013 Elsevier Ltd All rights reserved 303
Figure 3. The Luminal Taxoid Binding Site
(A and B) PTX (CPK coloring) in its binding site with the interacting amino acids.
(C) Overall view of PTX (CPK) in its binding site showing all interacting residues and secondary structures (the core helix 7 is shown in green, the M-loop in
magenta, the H6-H7 loop in purple, and the S9-S10 loop in blue).
(D) View of the b-tubulin subunit with PTX (CPK) in its binding site. The core helix H7 is shown in green, the M-loop in magenta, the S9-S10 loop in yellow, the
H6-H7 loop in purple, and the H1-H2 loop in blue.
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data from the Giannakakou laboratory, who described PTX- and
EPO-resistant cell lines (Giannakakou et al., 1997). PTX-resistant
cells have single amino acid changes at Ala374 (this residue is
a Ser in the bovine brain tubulin used in Figure 2) located in the
S9-S10 stabilizing loop and at Phe272 at the start of the
M-loop, both regions proposed to be in the binding site of PTX
(Nogales et al., 1999) (Table 2). Two EPO-resistant cell lines
also demonstrated cross-resistance to PTX. These cell lines
have single amino acid mutations at positions Thr276 and
Arg284, both amino acids having been shown to be directly
involved in PTX and EPO binding (Giannakakou et al., 2000). A
number of other mutant cell lines have also been described
that induce resistance to some but not all of the PTX-site
compounds, depending on how the MSAs interact with the
pocket (see Table 2 for details). In general, thesemutations occur
at specific sites within structural features that surround the
taxoid binding site or mediate contacts between two tubulin304 Chemistry & Biology 20, March 21, 2013 ª2013 Elsevier Ltd All rsubunits in the context of the protofilament. A number of these
mutations have been confirmed using random mutagenesis
and a number of new mutations identified, all of which showed
that mutations tended to cluster around the H6-H7 loop (Yin
et al., 2012). However, mutations outside the binding site could
still affect the ability of an MSA to bind due to allosteric or struc-
tural changes in tubulin. Tubulin mutations often cause changes
in the stability of aMT, evenwithout a drug, and thus themutated
amino acid may be completely outside the binding site of a
particular compound.
The Pore Site: A Two-Site Binding Hypothesis
Rapid staining of MTs with the fluorescently-labeled PTX analog
Flutax (FTX) led to speculation that PTX binds on the surface of
the MT, with the C7 and C10 moieties facing toward the solvent
(Evangelio et al., 1998). This is consistent with the finding that
PTX rapidly induces flexibility in MTs assembled in vitro, indi-
cating that access to the binding site is unhindered and fast
(Dye et al., 1993). However, the taxoid binding site modelights reserved
Table 1. Tubulin Regions and Amino Acid Residues Involved in PTX, EPOA, ZMP, LAU, and PEL Stabilization
Structural Features Residues Interactions References
Paclitaxel
H1 Gln15–Ser25 near C30of PTX Rao et al. (1994); Nogales et al. (1998)
H5 and H5-H6 Ile212–Pro222 near C2 Rao et al. (1995); Nogales et al. (1998)
M-loop Leu275 main interaction point with
taxane ring
Nogales et al. (1998)
M-loop Arg284 C7 contact Rao et al. (1999)
M-loop; H10-S2 Arg284, Glu55 salt bridge (in PTX-bound MTs) Mitra and Sept (2008)
M-loop Pro274, Leu275, Thr276,
Ser277, Arg278
interaction with taxane ring Nogales et al. (1999); Lo¨we et al. (2001)
H1 Val23 hydrophobic contact with 30 and
40 phenyl rings
Lo¨we et al. (2001)
H1 Asp26 H-bond distance with nitrogen
side chain
H6-H7 Leu217, Leu219 hydrophobic contact with C2
phenyl ring
H7 His229, Leu230 complete hydrophobic contacts
with C2 phenyl ring
H7 Ala233, Ser236 contact with 30 phenyl ring
S7 end Phe272 hydrophobic contact with 30 phenyl
M-loop Pro274, Leu275, Thr276 contact with oxetane ring
S9-S10 Pro360, Arg369, Gly370,
Leu371
binding pocket contacts
H7 Leu230, Ala233 hydrophobic basin holding C4
acetate ring
Snyder et al. (2001)
M-loop Phe274, Pro274, Thr276
(CH3), Leu286
H9 Leu291
S9-S10 Pro360, Leu371
S10 Ser374 (CH2)
M-loop Thr276, Gln281 C8 methyl van der Waals contacts
M-loop Thr276 O21 weak electrostatic interaction
S9-S10 Leu371 in proximity to C12
M-loop Ser277 side chain H-bond with C7 OH Freedman et al. (2009)
Epothilone A
H1 Asp226 OH7 H-bond with side chain oxygen Prota et al. (2013)
M-loop Thr276 O1 H-bond back bone NH2 and N20
H-bond side chain OH
M-loop Gln281 OH3 H-bond side chain amide nitrogen
M-loop Arg278–Tyr283 restructured into short well-defined helix
Zampanolide
H7 His229 C9 covalent bond with His side chain
NH (major)
Field et al. (2012)
H7 Asn228 C3 covalent bond with side chain
amide (minor)
M-loop Thr276 C20 OH and C10 carbonyl H-bond with
main chain carbonyl and NH2
Prota et al. (2013)
M-loop Arg278–Tyr283 restructured into a short well-defined
helix
Laulimalide (b subunit)
H10-S9 Asn339 H-bond with C15 OH and defines
cavity entrance
Bennett et al. (2010)
H9-H90, H10-S9 Phe296, Arg308, Tyr342 side chains protrude into binding
pocket and reorganize
(Continued on next page)
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Table 1. Continued
Structural Features Residues Interactions References
H9-H90, S8, H10, H10-S9 Phe296, Tyr312, Val335,
Asn339, Ser341, Tyr342,
Phe343, Ile347
residues with binding interactions in
pocket; O1 close to Asn339 side
chain NH, O3 epoxide to Tyr342
phenolic OH, C20 OH to backbone
NH of Ser341 and Tyr342
Nguyen et al. (2010)
S8 Tyr312 side chain pyran O7 H-bond to Tyr312
backbone NH2
H10-S9 Phe343 aromatic ring side chain pyran group stacked
H10-S9 Phe343 ring and Ile347
side chain
C28 methyl of pyran ring wedged
between residues
H10 Val335 pyran C5-9 packed against hydrophobic
side chain
H9-H90, S8 Phe296, Tyr312 aromatic
side chains
favorable binding surfaces with C30 CH3
and C29 CH2
H10-S9 Undefined C20 OH could H-bond with this loop and
residues may form water-mediated
H-bonds with LAU
Peloruside A (b Subunit)
Various b288–293, 296–303,
304–316, 334–343
important in binding pocket Huzil et al. (2008); Chen et al. (2008)
H9-H90, H90, H10-S9 Asp297, Ala298, Pro307,
Arg308, Asn339, Tyr342
pocket holding PEL macrolactone Huzil et al. (2008)
H9, H9-H90, H90 H10-S9 Gln294, Asp297, Arg308,
Asn339, Val335, Try342
side chains involved in pocket holding
macrolactone
H9-H90 Phe296 C26 wedged against side chain Nguyen et al. (2010)
H90 Arg308 guanidine
side chain
C9 and C11 hydroxyl long-range
electrostatic interactions or potential
water-mediated H-bonds or potential
intermittent H-bonds between
308 and OHs
H90 Arg308 side chain hydrophobic binding surface for PEL;
hydrophobic interactions with
C10 and C12
H90 Arg308 C27 interacts with aliphatic side chain
S8 Tyr312 hydrogen bond with C24 hydroxyl
S8 Tyr312 C10 CH3 groups wedged against
side chain, C23 interacts with
side chain
H10 Val335 C25 hydrophobic interaction
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was located in the lumen of the MT. Thus, it was proposed that
taxanes and other taxoid site ligands reach their luminal binding
site by diffusion through openings on the MT surface.
Openings in the MT wall were first observed in 1974 by Amos
and Klug (1974) and later modeled at high resolution (Nogales
et al., 1999). In the MT structure, two different types of pores
have been described, type I and type II. The type I pore has
the b subunit at its lower boundary (plus-end orientated upward),
with the luminal taxoid site in close proximity; whereas, the type II
pore has the a subunit at its lower boundary. The main differ-
ences between the two pores are changes in the H6-H7 loop
and the degree of hydrophobicity (Dı´az et al., 2003). The size of
one of these pores in the MT wall is considered too small for
passive diffusion of MSAs. Although pore size is comparable306 Chemistry & Biology 20, March 21, 2013 ª2013 Elsevier Ltd All rwith ligand size, diffusion would be extremely slow, and larger
openings are not consistent with the MT structure and kinetic
data. Diffusion of ligands from the openMT end is highly unlikely.
In addition, the binding of taxoids to the MT is slowed con-
siderably when MAPs are bound to the outer surface of the
MT. Further evidence against direct diffusion of MSAs to the
taxoid site is that PTX reaches its binding site too quickly (Dı´az
et al., 2003), with the number of protofilaments changing within
1 min of PTX addition (Dı´az et al., 1998). Also, as mentioned,
PTX rapidly modifies MT flexibility (Dye et al., 1993), and FTX
rapidly stainsMTs (Evangelio et al., 1998). Other work has shown
that the taxoid binding site is likely to be kinetically inaccessible
as it is hidden from the exterior in MT models (Nogales et al.,
1999). To explain the observed data in view of the structure of
the MT, a fast binding theory for ligands that target the taxoidights reserved
Table 2. Mutations in b-Tubulin that Confer Resistance to MSAs
Resistance to Cell Line WT Residue Mutated Amino Acid Location Reference
Paclitaxel 1A9-PTX10 Phe272 Val M-loop Giannakakou et al. (1997)
1A9-PTX22 Ala374 Thr S9-S10 loop
CHO Leu217 His, Arg, Phe H6-H7 loop Gonzalez-Garay et al. (1999)
CHO Leu219 Arg, Asn, Pro H6-H7 loop Gonzalez-Garay et al. (1999)
CHO Leu230 His, Phe H7 Gonzalez-Garay et al. (1999)
KB-3-1 Asp26 Glu H1 Hari et al. (2006)
Docetaxel LNDCr Phe272 Ile M-loop Hara et al. (2010)
Epothilone A 1A9-A8 Thr276 Ile M-loop Giannakakou et al. (2000)
HeLa Pro175 Ala T5-loop He et al. (2001)
Epothilone B 1A9-B10 Arg284 Gln M-loop Giannakakou et al. (2000)
HeLa Tyr434 Cys H12 He et al. (2001)
A549, CCRF-CEM, A549 Gln294 Glu H9 He et al. (2001); Verrills et al. (2003)
Yang et al. (2005)
CCRF-CEM Ala233 Thr H7 Verrills et al. (2003)
A549 Val62 Phe H10-S2 Yang et al. (2005)
Laulimalide 1A9-L4 308 His (70%); Cys (30%) H90 Kanakkanthara et al. (2011)
Peloruside 1A9-R1 Ala298 Thr H9-H90 loop Kanakkanthara et al. (2011)
1A9 Ala298 Ser H9-H90 loop Begaye et al. (2011)
1A9 Arg308 His H90
1A9 Asn339 Asp H10-S9 loop
1A9 Tyr342 Ser H10-S9 loop
Mutations in b-tubulin that confer resistance to MSAs. The ‘‘resistance to’’ column gives the MSA with which the cells were selected. 1A9 cells
(subclone of A2780), human ovarian carcinoma; CHO cells, Chinese hamster ovary; KB-3-1 cells, epidermoid carcinoma; LNDCr cells, human prostate
cancer; A549 cells, human nonsmall cell lung cancer; HeLa cells, human cervical adenocarcinoma; CCRF-CEM cells, leukemia (desoxy-EPOB not
EPOB used).
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external binding site exists. Pore type I describes the space
between a and b subunits from neighboring heterodimers,
specifically in the region of Phe214, Thr220, Thr221, and
Pro222 (H6-H7) (Figure 4). In this model, binding to both sites
is mutually exclusive, and both sites possibly share a ‘‘switching
element’’ that accompanies the two different binding modes.
This is supported by the 1:1 stoichiometry observed for taxoid
site ligands. Dı´az et al. (2005) demonstrated that fluoresceinated
taxoids could be labeled by an antifluorescein antibody, and this
would only occur if the molecule was bound at the surface, given
that antibodies cannot diffuse into the luminal compartment of
the MT. Additionally, doublecortin, a MAP known to bind to the
MT in a position that covers the pore site, causes MT assembly
(Moores et al., 2004); thus, a pore location for an assembly
promoter is not a new concept. In order to facilitate this move-
ment of anMSA from the outer site to the inner site, it is proposed
that there are conformational changes involving residues in the
external binding site moving in toward the luminal site and result-
ing in loss of the external site and formation of the internal site.
The H6-H7 loop in b-tubulin, which is flexible at Gly225 and
highly hydrophobic, may play a role in the initial binding of PTX
at the pore type I site, and this binding then assists in the trans-
location of PTX to the luminal site (Dı´az et al., 2003). This loop is
also involved in the luminal binding site, with Leu217 and Leu219
making hydrophobic contact with PTX (Lo¨we et al., 2001), and
mutations in this loop are associated with PTX resistanceChemistry & Bio(Gonzalez-Garay et al., 1999; Yin et al., 2012). Using computa-
tional analysis, it has been proposed that arrangement of the
H6-H7 loop causes the formation of an external binding pocket
large enough to accommodate an MSA. The same computa-
tional analysis was applied to the other pore site on the dimer,
pore type II; however, no binding pocket was seen, indicating
that the proposed external binding site is likely only found at
pore type I (Magnani et al., 2009). This binding model describes
taxoid site drugs binding to the temporary pore type I site on the
surface of the MT with the H6-H7 loop acting to transport the
ligand from the pore site to the luminal site (Dı´az et al., 2003,
2005; Buey et al., 2007; Magnani et al., 2009). Thus, pore
type I acts as a transition station for compounds passing through
to the luminal PTX binding site. This hypothesis is supported by
the fact that 7-Hexaflutax (fluorescent taxoid derivative), which
only binds to the pore type I site, has similar MT-stabilizing
activity to compounds that bind to the luminal site. This suggests
that the pore type I site can be probed as a new druggable site on
MTs (Dı´az et al., 2005; Barasoain et al., 2010). The existence of
this external site is also supported by indirect NMR evidence
for a low affinity binding site for MSAs, in which measurements
done with DTX and DSC support the idea that a site with much
lower affinity, not the luminal site that has high affinity for taxoid
site MSAs, is responsible for recognition of theseMSAs (Canales
et al., 2008, 2011).
Consistent with this external binding site hypothesis, a re-
cently discovered MSA, CYC, the first MSA identified to bindlogy 20, March 21, 2013 ª2013 Elsevier Ltd All rights reserved 307
Figure 4. Pore Type I Site
Beta subunit showing the M-loop (magenta) and the H6-H7 loop (purple).
Important residues are highlighted. GLY225 (yellow) is thought to act as
a hinge in the movement of this loop between the pore site and the luminal
binding site. Note that this image has been made from zinc-stabilized sheets,
and therefore the H6-H7 loop is in its luminal binding site conformation rather
than the pore site. Thus, this is not a true representative pore site image and
only shows interacting components.
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irreversibly competes with taxoid site drugs and covalently
modifies two amino acids in b-tubulin, Thr220, located in pore
type I, and Asn228, located near the taxoid site with its side chain
facing into the E-site. In unpolymerized tubulin, only Thr220 is
labeled by CYC, indicating that the pore type I is in fact a binding
site and suggesting that pore type I may be the only binding site
for MSAs in dimeric tubulin (Buey et al., 2007).
To summarize, binding of MSAs to the taxoid site is proposed
to occur in a two-stepmechanism (Dı´az et al., 2000), with the first
step being binding to the pore type I site on the outside of the MT
(Buey et al., 2007) from which the MSA dissociates with fast
kinetics (Dı´az et al., 2000). The second step is a slow reaction
that involves a shift of the MSA to the internal binding site. These
events would be reversed for dissociation of the MSA from the
MT, with translocation from the luminal site to the external pore
site being the slow step and the second step being the fast
release of the ligand from the pore site. This hypothesis explains
howPTX can reach the kinetically unfavorable site in the lumen of
the MT. Freedman et al. (2009) tested this hypothesis using
computational molecular modeling and confirmed that the
H6-H7 loop in the pore acted as a hinge in the first binding
step of PTX. This motion was stabilized by a H-bond with
Ser277 located in the M-loop. This residue is an alanine rather
than a serine in bIII- and bVI-tubulin isotypes (Freedman et al.,
2009), and the fact that bIII-tubulin is less sensitive to PTX than
bI-tubulin (see review by Burkhart et al., 2001) further supports
the role of Ser277 and H6-H7 loop motion.
Arguing against the two-step binding hypothesis, Prussia et al.
(2010) claim that a low affinity site on the exterior of the MT is not
necessary to explain the available data. They base their con-
clusion on results of molecular dynamics and modeling work308 Chemistry & Biology 20, March 21, 2013 ª2013 Elsevier Ltd All rthat suggests that the shape and lipophilic character of pore
site I make it an unlikely binding site for MSAs. It is proposed
that the pore simply slows MSA diffusion into the interior of the
MT, acting like a ‘‘funnel’’ or channel without a distinct binding
event occurring. It is further suggested that the fast binding
kinetics of MSAs can be explained by a pause in the diffusion
of the ligand traveling through the pore via transient interactions
with specific residues, explaining the observed rapid binding.
This would be consistent with CYC labeling of Thr220 because
it is located in the narrowest part of the pore. Overall, it is
proposed by Prussia et al. (2010) that the concept of a binding
site at the pore is an artifact of the slow diffusion through the
pore into the luminal site, with the pore being nothing more
than an entry site.
In contrast to the Prussia model, the evidence supporting
the pore type I binding site has been accumulating over the
last few years, and includes the previously discussed 7-hexa-
flutax binding behavior and data on the binding kinetics of
FTX-2, both of which suggest that the interaction is specific
(Dı´az et al., 2005; Barasoain et al., 2010). A recent study of
CYC analogs has shown that two of the analogs also covalently
modify Thr220 (Calvo et al., 2012), again supporting pore type I
as an MSA binding site. The current overall consensus is that
MSAs may bind either the luminal or pore site in unassembled
tubulin; whereas, in MTs it is likely that they first bind pore
type I (fast kinetics) and then move into the luminal binding site
with the assistance of residues in the H6-H7 loop. This is consis-
tent with and explains the majority of the data currently available
in the field.
From the above studies, it is still not clear whether PTX and its
biomimetics bind to only the inner, only the outer, or to both sites,
even though it is known that taxoids bind in a 1:1 stoichiometry
(Dı´az and Andreu, 1993; Dı´az et al., 2000) and that binding to
either site on its own causes tubulin assembly (Barasoain
et al., 2010). Both sites utilize the residues in the H6-H7 loop,
indicating that when a ligand is bound at one site, binding to
the other site is not possible. Thus, ZMP (which binds the luminal
site) and 7-Hexaflutax (which binds pore site I) cannot bind at the
same time (Field et al., 2012; Magnani et al., 2009). Therefore,
binding to either site prevents binding to the other, and likely
involves a switching element between the two sites, such as
the H6-H7 loop. Cryo-electron microscopy of doublecortin-
stabilized MTs indicates that the taxoid binding pocket is empty
(Fourniol et al., 2010). It is therefore likely that the pore site is
a transient binding site for taxoid site compounds on their way
to their final destination in the lumen.
The Luminal Binding Site in Unassembled Tubulin
MSAs promote the assembly of tubulin heterodimers into MTs,
shifting the equilibrium toward the polymeric state. MSAs were
not originally thought to bind with measurable affinity to unas-
sembled tubulin, because it was believed the taxoid binding
site only existed in assembled MTs (Parness and Horwitz,
1981; Dı´az and Andreu 1993). Interprotofilament contact was
therefore assumed to be required for binding to the taxoid site.
It is now accepted that MSAs can bind to dimeric tubulin
because they are able to induce the formation of MTs in condi-
tions unfavorable to MT assembly, conditions in which no MTs
exist. This has now been confirmed by direct biochemical
studies with ZMP and X-ray crystallography (Field et al., 2012;ights reserved
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stabilized sheets is similar to that in unassembled tubulin, with
only small structural differences (Prota et al., 2013).
Ligand binding to dimeric tubulin is necessary to explain the
way in which MSAs work. An MSA must have a binding affinity
higher for the assembled species than the dimeric species
(Dı´az et al., 1993; Canales et al., 2011). Given this higher free
energy of binding toward polymerized MTs, the equilibrium
would displace toward the polymer (Wyman and Gill, 1990).
Because MSAs can induce MT assembly in conditions in which
no preformed MTs exist, it is reasonable to predict that a lower
affinity site on dimeric tubulin starts the assembly process. The
first experimental proof of this low affinity site was based on
the detection of NMR signals with MSA binding (Carlomagno
et al., 2003; Sa´nchez-Pedregal et al., 2006; Canales et al.,
2008, 2011).
Until recently, there has been no direct biochemical evidence
for the luminal site existing in dimeric tubulin. Nuclear magnetic
resonance (NMR) and computational studies have now provided
evidence of a low affinity site on dimeric tubulin (Canales et al.,
2008, 2011) as well as low affinity binding of MSAs to non-
homogeneous tubulin preparations (Carlomagno et al., 2003;
Sa´nchez-Pedregal et al., 2006). From these studies, however,
it is not possible to determine whether binding is at the pore
site or at the luminal site. It has now been shown that ZMP
and DAC covalently modify two amino acids within the luminal
binding site of the isolated heterodimer, providing the first direct
evidence that the luminal binding site exists in tubulin dimers
(Field et al., 2012). Therefore, as previously proposed by
Canales et al. (2011) and Reese et al. (2007), MSAs can
bind to both the luminal site and the pore type I site in un-
assembled tubulin. The exception, of course, is CYC that can
only bind the pore site in the dimer. The existence of the luminal
site is also supported by the X-ray crystallographic structures of
ZMP and EPOA bound to unassembled tubulin (Prota et al.,
2013).
Binding of Other MSAs to the Taxoid Site
After the taxanes, the next most important MSAs are the EPOs,
given that an analog (Ixempra) is currently approved for use in the
clinic. The detailed binding interactions of EPOA with the MT
were first solved to 2.9 A˚ resolution by electron crystallography
using zinc-stabilized sheets (Nettles et al., 2004). This gave
direct evidence that the taxanes and EPOs share the same
binding region, as previously thought. Recently, the X-ray crys-
tallography structure of EPOA bound to unassembled tubulin
has been solved to 2.6 A˚ (Prota et al., 2013). Thismodel contrasts
with the earlier model, possibly because the X-ray crystallo-
graphic model is more defined, allowing for a clearer interpreta-
tion of the conformation and orientation of the bound ligand. In
the model by Prota et al. (2013), EPOA forms four H-bonds
with residues in the taxoid site (Table 1) that are all key partici-
pants in PTX binding. When EPOA is bound, it induces restruc-
turing of the M-loop into a short and well-defined helix with resi-
dues 278–283 forming a number of hydrophobic and polar
contacts with the side chain of EPOA and stabilized by intramo-
lecular H-bonds between theM-loop and the H9.When no ligand
is bound, the M-loop is relatively unstructured. This restructuring
is now thought to be the underlying molecular basis of stabiliza-
tion by MSAs (Prota et al., 2013).Chemistry & BioDSC is a taxoid site MSA with a unique profile relative to the
taxanes. DSC competes with PTX for binding to MTs (Hung
et al., 1996) but can also synergize with PTX, suggesting differ-
ences in binding modes (Martello et al., 2000). Unlike other
MSAs, DSC is a more flexible, linear compound (Figure 1). A
photo-labeled DSC analog labeled residues that form part of
S9 and the S9-S10 loop in b-tubulin (Xia et al., 2006) and are in
close vicinity to the taxoid site (Lo¨we et al., 2001). Given the
synergy seen between PTX and DSC, the two compounds
presumably have distinct poses in the site. Using chicken
erythrocyte tubulin, PTX was shown to bind to the luminal taxoid
site, orientated toward the M-loop, stabilizing the b-tubulin side
of the interdimer; whereas, DSC is orientated away from the
M-loop—more toward the H1-S2 loop and stabilizing the
a-tubulin side of the interdimer interface (Khrapunovich-Baine
et al., 2009). In support of this distinct binding mode, DSC has
previously been shown to be active in PTX-resistant human cells
(Kowalski et al., 1997).
ZMP and DAC also target the taxoid binding site; however,
they do so in a different manner to the traditional MSAs, cova-
lently attaching to His229 (major product) and Asn228 (minor
product). Solving the ZMP-tubulin structure by X-ray crystallog-
raphy to 1.8 A˚ resolution has provided an accurate binding site
for ZMP in unassembled tubulin (Prota et al., 2013). As the
previous model proposed, ZMP covalently binds to His229 in
the taxoid binding pocket; however, the placement of the ZMP
side chain conflicts with the earlier modeling predictions. ZMP
forms two H-bonds with M-loop residue Thr276. The ZMP side
chain induces restructuring of the M-loop into a short, well-
defined helix, much like the side chain of EPOA. Although their
side chains superimpose well, their macrolide cores are oriented
90 to one another, held in the taxoid site by different sets of
interactions. This induced helical structuring of the M-loop is ex-
plained by the extensive hydrophobic and polar contacts formed
between the side chain of ZMP and M-loop residues, as seen
with EPOA. This helical M-loop restructuring is now considered
a ‘‘hallmark’’ of MSA binding and explains the effect of these
MSAs on MT assembly and stabilization. It also explains why
MSAs have higher affinity for MTs compared to unassembled
tubulin, because the M-loop is already ordered in MTs (Prota
et al., 2013).
The Laulimalide/Peloruside Binding Site
The second major MSA binding site on the MT is shared by LAU
and PEL and is biochemically distinct from both the taxoid site
(Pryor et al., 2002; Gaitanos et al., 2004) and the pore type I
site (Buey et al., 2007). The location of the site was highly
debated as there was evidence to support its location on both
the a and b subunit, and structural studies using zinc-stabilized
tubulin sheets have so far been unsuccessful because the sheets
were unable to be formed with LAU (Thepchatri et al., 2005). The
binding site for LAU was first localized to the S9-S10 loop region
on the a-tubulin subunit (Pineda et al., 2004). This site was sup-
ported by NMR describing the bioactive conformation of PEL
bound to the a subunit, with interactions centered on the
aM-loop (Jime´nez-Barbero et al., 2006). A more recent study
showed that PEL analogs with substitutions at C24 lose their
polymerizing activity (Pera et al., 2010). From the above studies,
the LAU/PEL site appeared to be located on a-tubulin in a zone
equivalent to that occupied by PTX in b-tubulin (Figure 5A).logy 20, March 21, 2013 ª2013 Elsevier Ltd All rights reserved 309
Figure 5. Models of the Proposed LAU/PEL Sites
(A) Model of the proposed site on a-tubulin showing the core helix (green), the M-loop (magenta), the S9-S10 loop (blue), and the eight extra amino acids of the
S9-S10 loop (purple). Amino acids important in PEL binding to the a subunit are colored in yellow. ARG320 (red) H-bonds with PEL. GTP is colored in CPK.
(B) Model of the proposed binding site on b-tubulin. Secondary structures are colored as for (A), but note the missing purple residues in this subunit. The peptides
shown in cyan are those identified by Huzil et al. (2008) using HDX-MS. Interacting residues are shown in yellow and red. Those in red are the amino acids that are
mutated in the different LAU/PEL resistant cell lines.
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extra amino acids (Figure 2). These residues are thought to
occlude this site and cause stabilization of the aM-loop, giving
extra strength to the lateral contacts between a subunits in
different protofilaments (Nogales et al., 1999; Fourniol et al.,
2010); thus, it seems unlikely an MSA would bind in this region.
Using hydrogen-deuterium exchange mass spectrometry
(HDX-MS), Huzil et al. (2008) first proposed that the PEL binding
site was located on the exterior surface of the b subunit, in
a cavity near the ab subunit interface. Although this b subunit
site is relatively close to the taxoid site in sequence, it is struc-
turally distant, with the macrolactone moiety of PEL held in
a distinct pocket (Table 1; Figure 5B). Using digital signal pro-
cessing, a technique that detects hot spots on the protein where
binding occurs, a region nearly identical to that originally
proposed by Huzil et al. (2008) was identified as the PEL binding
site (Chen et al., 2008). This b subunit site was then indepen-
dently supported by modeling and biochemical studies with
[3H]-PEL that provided a more rational structural basis for
binding and a greater array of hydrophobic and electrostatic
interactions with the b-site relative to binding at the a-site
(Nguyen et al., 2010). Although this model proposed binding to
the same site, PEL was orientated differently and generated
more H-bonds to the model proposed by Huzil et al. (2008)
(Table 1). Specifically, an intramolecular H-bond is formed that
stabilizes the orientation and allows interaction of hydroxyl
groups with Arg308, and the side chain of Arg308 provides an
important hydrophobic platform for PEL. In the Nguyen et al.
(2010) model, the macrolide cores of LAU and PEL lined up,
and modification at C24 would reduce binding due to loss of
a H-bond with Tyr312, consistent with the findings by Pera
et al. (2010). Another study in the Schriemer lab (Bennett et al.,
2010) used mass shift perturbation analysis and data-directed
molecular docking simulations to show that LAU binds on the310 Chemistry & Biology 20, March 21, 2013 ª2013 Elsevier Ltd All rexternal surface of the MT. The site was located near the intra-
dimer interface, just above the colchicine binding site, in the
vicinity of the type II pore. This makes the LAU/PEL site unique
by its being located on the outside of the MT near pore type II;
whereas, all other MSA and MDA sites, except for the less
characterized pore type I site, are located on the inner interfaces
of the MT. Binding at this external site would cause reorganiza-
tion of the side chains that protrude into the binding cavity,
thus promoting the stabilization of this region. A more recent
paper using HDX-MS supported the b subunit binding site,
concluding that the a-site was unlikely for PEL and LAU binding
(Khrapunovich-Baine et al., 2011).
Biological support for the above modeling was recently
provided from mutation mapping following long-term exposure
of cells to stepped concentrations of MSAs. Mutations to resi-
dues important for PEL and LAU binding impaired tubulin poly-
merization in the presence of either PEL (Ala298Thr) or both
LAU and PEL (Arg308His/Cys), but not to taxoid site agents
(Kanakkanthara et al., 2011). A subsequent study described
four resistant cell lines, two that were identical to those previ-
ously described and two new mutations Tyr342Ser and
Asn339Asp (Begaye et al., 2011). The four mutations all centered
on a cleft that may interact with the side chain of PEL (Huzil et al.,
2008), and all four mutations conferred resistance to PEL and
showed cross-resistance to LAU (Table 2). Both of these cell-
based studies supported the b-tubulin location of the binding
site rather than a-tubulin, and both highlighted the importance
of the side chain cavity. Residue Arg308 is essential in defining
the entrance into the deep, narrow hydrophobic cleft in which
the side chains of both compounds penetrate, and muta-
tions in Arg308 caused the greatest resistance of the cells.
LAU is thought to reorganize the side chains of amino acids
that point into this cleft to cause stabilization of this region
through stabilization of Arg308 via its interactions with Tyr342ights reserved
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important in PEL binding, which instead may involve interactions
between residues Arg308 and Ala298 (Begaye et al., 2011)
(Figure 5B). At this stage, it is likely that LAU and PEL bind to
the b-tubulin site first proposed by Huzil et al. (2008), but addi-
tional confirmation by X-ray crystallography is required to defin-
itively prove this location.
Although it is possible that LAU and PEL may bind at both the
described a and b subunits sites, stoichiometry studies giving
1:1 ratios of binding do not support simultaneous binding (Pera
et al., 2010). Thus the a- and b-sites, if both exist, must be mutu-
ally exclusive, similar to the taxoid site and the pore type I site.
Pera et al. (2010) suggest that, like the taxoid site drugs, LAU
and PEL may have a two-step binding mechanism in which
binding would involve an initial event, possibly an interaction
with the b subunit, given the proximity of this proposed site to
pore type II, followed by binding at the a-tubulin site. It is also
possible that the initial binding site may be with low affinity on
the a subunit, because this is the site that is picked up by
NMR studies, with the final binding on the b-tubulin site. This
alternative mechanism better explains the fact that mutations
in resistant cell lines are only found in the b subunit, much like
the resistant cell lines described for PTX that have mutations in
the luminal binding site rather than the pore type I site (Gianna-
kakou et al., 1997). It is not uncommon for drugs to have
a two-step binding mechanism. For example, the MSD colchi-
cine and a number of its analogs bind in a two-step mechanism
in which the first step is slow and occurs with low affinity binding,
followed by a conformational change causing high affinity bind-
ing (Skoufias andWilson, 1992). The difference here, however, is
that two distinct colchicine binding sites do not exist, but two
subsites are found in a single region of b-tubulin.
Mechanisms of Stabilization
Thermodynamically, MSAs and MDAs are molecules that
change the ratio between polymerized MTs and unassembled
tubulin. They do this by binding preferentially to either tubulin
polymers or tubulin dimers. Ligands binding preferentially to
dimers inhibit assembly of MTs; whereas, ligands binding prefer-
entially to MTs prevent disassembly (Dı´az et al., 2009). This is
due to thermodynamic linkage and is independent of where the
binding site is or changes in structural dynamics on binding. A
common thermodynamic mechanism of assembly induction
can be proposed for reversible MSAs. Reversible MSAs bind
the assembled form of tubulin tightly, but not covalently;
whereas, they do not bind the unassembled form with measur-
able affinity (Dı´az et al., 1993). The main thermodynamic driving
force for their induced assembly is the difference in their binding
constants for dimeric tubulin relative to assembled tubulin. For
example, the binding constant of DSC for the dimer (Canales
et al., 2011) is significantly lower than that for stabilized MTs
(Buey et al., 2005). In structural terms, the difference in affinity
and thus the mechanism of assembly induction should arise
from a difference in binding site conformation. In unassembled
tubulin, in the absence of an MSA, the M-loop is disordered;
whereas, in MSA-bound unassembled tubulin, a short well-
defined helix is formed, with the rest of the taxoid site binding
pocket remaining unchanged (Prota et al., 2013). In unligated
dimers, the M-loop has to undergo a structural change in orderChemistry & Bioto accommodate the ligand, and the related free energy has to
be subtracted from the overall free energy of the newly formed
MSA/protein interactions. In MTs, this M-loop may already be
in a helical structure, and no rearrangements are needed to
bind the MSA. It is evident that the linked assembly binding
process should have an energetic advantage of 30 kJ/mol
over the assembly process even if the restructuring is energeti-
cally negative. These differences in binding constants would
drive the reaction toward the assembled state.
The case would be entirely different for an irreversible binding
compound such as ZMP. In this case there is no reaction equilib-
rium (no off-rate of covalently bound ZMP), and the reaction is
only kinetically controlled by the formation of the covalent
bond. The energy of restructuring would be irrelevant because
there are two different molecules with different structures,
tubulin and the ZMP-tubulin adduct. Once ZMP has bound
irreversibly, the M-loop residues have a different equilibrium
conformation as a result of new bonds forming that are different
from the M-loop residues in the unligated protein. This confor-
mational change of structuring, energetically unfavorable in the
case of the unligated protein, is necessary to form the lateral
contacts, and the difference in the equilibrium polymerization
of free energy of both processes is a reflection of the energetic
cost of M-loop restructuring. In ligated tubulin, restructuring
has already occurred prior to the lateral contacts being made;
thus, ligated tubulin assembly will have lower free energy than
unligated tubulin assembly.
Taxoid Site-Binding Stabilization
The knowledge on how MSAs bind to and stabilize MTs has
initially come from using PTX as a probe. Muchmore information
is known about this mode of stabilization and very little about
LAU/PEL stabilization, especially given that neither LAU nor
PEL is commercially available. Binding of an MSA to the taxoid
site strongly influences the interactions at three key regions
within the tubulin molecule, the M-loop, H3, and S3 (Matesanz
et al., 2011), all of which are known to be important for interpro-
tofilament interactions (Nogales et al., 1998). This binding
causes increased lateral contacts by facilitating the key interac-
tion of the b subunit M-loop with the two loops (H10-S2 and
H2-S3) in a neighboring protofilament, resulting in stabilization
of the MT (Amos and Lo¨we, 1999; Nogales et al., 1999; Sui
and Downing 2010). PTX, however, is able to stabilize zinc-
induced tubulin sheets that have an alternating and antiparallel
arrangement to one another, and this orientation of the subunits
limits this M-loop interaction (Amos and Lo¨we, 1999; Mitra and
Sept, 2008). In addition, PTX also stabilizes individual protofila-
ments via stabilization of longitudinal contacts (Elie-Caille
et al., 2007); thus, PTX must cause stabilization by another
mechanism at the same time as it increases lateral protofilament
interactions (Mitra and Sept, 2008). PTX sterically hinders the
natural movement of the M-loop, having a significant effect on
its conformation and causing displacement of the loop down-
ward and away from H6. This results in increased interactions
with the loops in an adjacent monomer via van der Waals forces
and electrostatic and ionic interactions, increasing the dynamics
of the H1-H2 loop and also affecting the H6-H7 loop to some
extent (Mitra and Sept, 2008). Orientation and dynamics depend
on which taxoid site ligand is bound to the site (Matesanz et al.,
2011). Specifically, a stable salt bridge is formed between Glu55logy 20, March 21, 2013 ª2013 Elsevier Ltd All rights reserved 311
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when PTX is bound. In the absence of PTX, a salt bridge is
formed between Arg284 and a residue in the same monomer
that leads to a change in the M-loop, causing a small opening
of the taxoid binding site. This opening may assist in the binding
of PTX (Mitra and Sept, 2008). MSA interactions at the taxoid site
occur close to the interprotofilament region of theMT and dictate
the number of protofilaments making up the MT. PTX decreases
the number of protofilaments making up the MT from 13 to 12 in
purified tubulin (Andreu et al., 1992); whereas, DTX binding has
no effect on the number of protofilaments (Andreu et al., 1994).
This suggests that different MSAs can alter the way in which pro-
tofilaments laterally interact, changing the number of protofila-
ments in a MT and the interprotofilament angle (see Matesanz
et al., 2011). Increasing the strength and duration of interactions
between protofilaments should cause overall stability of the MT,
but it is questionable whether these interactions would be
sufficient to promote assembly of MTs from GDP-bound dimers.
After nucleotide hydrolysis, the MT becomes unstable
because of its straight, constrained conformation. However, in
the presence of PTX, the MTs remain stable, even when GDP
is bound to the E-site. This maintained stability is thought to be
due to strong longitudinal and lateral binding between dimers
in adjacent protofilaments. If certain bonds are weakened by
hydrolysis, PTX must somehow compensate for this in such
a way that the MT remains stable. This can occur by increasing
the strength and duration of lateral bonds; however, there is
controversy over this because PTX increases the flexibility within
the MT (although the opposite has also been reported). Currently
it is accepted that PTX increases MT flexibility (Sui and Downing,
2010), and it is possible that these lateral bonds may also be
flexible. Although there is debate over the exact mechanism, it
is likely that PTX causes changes in the nucleotide binding site
that compensate for the hydrolysis and allow the straight confor-
mation of theMT to remain stable (Amos and Lo¨we, 1999). This is
supported by the fact that PTX has allosteric effects on the T1–T5
and H11 loops (E-site), and these effects cause an increase in
flexibility, compensating for the GTP hydrolysis (Amos and
Lo¨we, 1999; Mitra and Sept, 2008). This in turn counteracts the
conformational change, thus promoting stability and leading
to a straighter, less strained protofilament. These allosteric
changes are thought to be the primary effect of PTX, with lateral
interactions a secondary means of stabilization. Alternative
hypotheses have been reviewed by Mitra and Sept (2008).
X-ray crystallography has shown that the taxoid binding site is
only slightly affected by the curved to straight conformational
change, with only minor rearrangements of the residues shaping
the pocket (Prota et al., 2013). Additionally, all crystal structures
of unassembled tubulin with bound MSAs are in the curved
conformation, as discussed above. The data presented in Prota
et al. (2013) also confirm that MSAs activate tubulin via restruc-
turing of the M-loop into a short and well-defined helix. This
structural change may be the molecular basis of the curved-to-
straight conformational change that is observed upon tubulin
assembly and predicts that the loss of this helical structure
would be an important feature of disassembly.
Insights into Laulimalide/Peloruside Site Stabilization
Although the taxoid site and the LAU/PEL site are biochemically
distinct, binding at either site results in the same end point—312 Chemistry & Biology 20, March 21, 2013 ª2013 Elsevier Ltd All rstabilization of the MT. Interestingly, the taxoid site and the
proposed b subunit site for LAU/PEL are located close to each
other in the amino acid sequence with H9 involved in the LAU/
PEL interaction, located C-terminal of the M-loop. Therefore,
LAU and PEL binding at the proposed b-tubulin site may induce
some level of stabilization of the M-loop, enough to cause
enhanced protofilament contacts and a more stable MT struc-
ture, a mechanism similar to that of PTX and its biomimetics
(Bennett et al., 2010).
A contrasting hypothesis is that LAU/PEL binding to the
b-tubulin site causes stabilization of the intradimer interface
(Bennett et al., 2010), returning the polymer to a more ‘‘GTP-
like state.’’ GTP bound at the E-site gives a stable form of tubulin,
which is why there is always a GTP cap on a growing MT. Occu-
pancy at the E-site changes the proposed LAU/PEL site, with
GDP destabilizing the MT via residues b304–312. Interestingly,
Jime´nez-Barbero et al., (2006) have provided some evidence
for docking of PEL at the E-site, but ruled this out as a true
binding site; however, their results can be explained by the
above observations. Thus, LAU could reduce the tension within
the MT lattice by binding at the E-site (Bennett et al., 2010).
PEL and LAU were suggested to cause the same stabilization
as taxoid site drugs via effects at the interdimer interface with
contributions from the ab-intradimer interface as well as protofi-
lament contacts (Huzil et al., 2008; Bennett et al., 2010). In addi-
tion, however, it was suggested that the binding of PEL was
complemented by relaxation of the intradimer interface and b-b
interactions at the lateral interface—a distinct stabilization
mode for PEL different to that of taxoid site drugs. Most MSAs
cause a conformational change in the T5 loop (located adjacent
to the E-site), promoting improved interactions across the inter-
dimer interface and resulting in stabilization of this interface and
possibly compensating for the lost stability when GTP hydrolysis
occurs (Huzil et al., 2008).
Allosteric versus Matchmaker Mechanisms
of Nucleation
When tubulin is at a critical concentration in which polymeriza-
tion is favored over depolymerization, MTs assemble via nonco-
valent, nucleated condensation polymerization. These reactions
are characterized by cooperative behavior (Dı´az et al., 1993).
Ligand-induced MT assembly also proceeds with a critical
concentration that is less than in the absence of ligand and is
concentration-dependent (Dı´az et al., 2009). The disruption of
MT polymerization dynamics appears to be themainmechanism
by which MT-stabilizing drugs function, and they do so without
a significant effect on polymer mass (Nogales, 2000). Given
that there are at least two, and likely three, different MSA binding
sites on MTs, the luminal taxoid site, the pore type I site, and the
LAU/PEL site, and given the extreme structural diversity of MSAs
that bind the MT, especially at the taxoid site, all MSAs are
unlikely to have exactly the same structural effects at the molec-
ular level (Dı´az et al., 2009). It is well known that MSAs promote
tubulin assembly in conditions where tubulin is unable to
assemble on its own, such as when no GTP or glycerol is present
in the buffer or when GDP is bound to the b subunit (Dı´az and
Andreu 1993; Parness and Horwitz 1981). Therefore, MSAs are
involved in the nucleation-elongation step of MT assembly.
MSAs are proposed to bind to unassembled tubulin with lowights reserved
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Reviewaffinity and induce polymerization via two possible mechanisms.
Either they promote a conformational change resulting in the
activation of the dimer or they join two subunits together to
form a high affinity site from two lower affinity sites. These two
mechanisms are termed the allosteric and matchmaker
processes, respectively (Dı´az et al., 1993, 2009; Reese et al.,
2007). The binding of an MSA to the dimer is the first in a series
of events that leads to the MSA-induced stabilization of MTs
(Sa´nchez-Pedregal et al., 2006). CYC modifies the pore site in
dimeric tubulin (Buey et al., 2007), and ZMPmodifies the luminal
binding site (Field et al., 2012; Prota et al., 2013). Binding at the
pore site in dimeric tubulin supports the matchmaker mecha-
nism in which the full pore site is formed from two half sites.
Binding at the luminal site in dimeric tubulin supports the allo-
steric mechanism of MSA-induced assembly in which the
internal taxoid site is present in dimers but has low affinity for
MSAs, and the high affinity site develops after assembly (Dı´az
et al., 1993). An alternative allosteric mechanism could involve
binding to the luminal site to activate tubulin, leading to nucle-
ation (Field et al., 2012). More recently, the allosteric model
has been directly supported by X-ray crystallography of both
EPOA- and ZMP-bound tubulin (Prota et al., 2013).
Future Investigations
Given the success of MSA chemotherapy in the clinic, the
numerous compounds at different stages of preclinical and
clinical development, and the novel agents still being dis-
covered, the biochemistry of MSAs remains an expanding area
of research. The next logical step in this exciting field would be
to determine the exact molecular mode of action in which
MSAs bind to the MT and cause stabilization. This is likely to
take time, given the complexity of the interactions. It is also likely
that taxoid site drugs bind via a two-stepmechanism, interacting
first at the surface of the MT followed by translocation into the
lumen. It would be interesting to see how this occurs and if every
ligand that targets the taxoid site follows the same two-step
process. The exact location of the LAU/PEL site also needs to
be determined. A two-step binding mechanism may also exist
at this site, with the two separate sites displaying different affin-
ities for LAU and PEL. A complete understanding of the molec-
ular mechanisms underlying MT stabilization is essential for
understanding the MSAs currently in clinical use. It is possible
that LAU and PEL have advantages over the taxoid site ligands
because they are poor substrates for the drug efflux pump and
they are more polar. This suggests that unlike PTX they may
not require a vehicle for delivery, thus decreasing toxic side
effects. There is also evidence that PEL is better tolerated in vivo.
It would therefore be worthwhile to develop these drugs or their
analogs for translation to the clinic. Overall this field of research
is exciting and has great potential for development of new drugs
to treat solid tumors. Despite the focus on targeted treatments,
chemotherapy-based cancer treatment still remains an impor-
tant approach in the fight against cancer.
ACKNOWLEDGMENTS
This work was supported by grants from the Cancer Society of New Zealand
(to J.H.M.) and the Wellington Medical Research Foundation (to J.H.M.),
BIO2010-16351 (to J.F.D.), and CAM S2010/BMD-2457 (to J.F.D.). J.H.M. is
named on a U.S. patent for peloruside A.Chemistry & BioREFERENCES
Akhmanova, A., and Steinmetz, M.O. (2008). Tracking the ends: a dynamic
protein network controls the fate of microtubule tips. Nat. Rev. Mol. Cell
Biol. 9, 309–322.
Amos, L.A. (2011). What tubulin drugs tell us about microtubule structure and
dynamics. Semin. Cell Dev. Biol. 22, 916–926.
Amos, L.A., and Klug, A. (1974). Arrangement of subunits in flagellar micro-
tubules. J. Cell Sci. 14, 523–549.
Amos, L.A., and Lo¨we, J. (1999). How Taxol stabilises microtubule structure.
Chem. Biol. 6, R65–R69.
Andreu, J.M., Bordas, J., Dı´az, J.F., Garcı´a de Ancos, J., Gil, R., Medrano, F.J.,
Nogales, E., Pantos, E., and Towns-Andrews, E. (1992). Low resolution struc-
ture of microtubules in solution. Synchrotron X-ray scattering and electron
microscopy of Taxol-induced microtubules assembled from purified tubulin
in comparison with glycerol and MAP-induced microtubules. J. Mol. Biol.
226, 169–184.
Andreu, J.M., Dı´az, J.F., Gil, R., de Pereda, J.M., Garcı´a de Lacoba, M., Peyrot,
V., Briand, C., Towns-Andrews, E., and Bordas, J. (1994). Solution structure of
Taxotere-induced microtubules to 3-nm resolution. The change in protofila-
ment number is linked to the binding of the Taxol side chain. J. Biol. Chem.
269, 31785–31792.
Barasoain, I., Garcı´a-Carril, A.M., Matesanz, R., Maccari, G., Trigili, C., Mori,
M., Shi, J.Z., Fang, W.S., Andreu, J.M., Botta, M., and Dı´az, J.F. (2010).
Probing the pore drug binding site of microtubules with fluorescent taxanes:
evidence of two binding poses. Chem. Biol. 17, 243–253.
Begaye, A., Trostel, S., Zhao, Z.M., Taylor, R.E., Schriemer, D.C., and Sackett,
D.L. (2011). Mutations in the b-tubulin binding site for peloruside A confer
resistance by targeting a cleft significant in side chain binding. Cell Cycle 10,
3387–3396.
Bennett, M.J., Barakat, K., Huzil, J.T., Tuszynski, J., and Schriemer, D.C.
(2010). Discovery and characterization of the laulimalide-microtubule binding
mode by mass shift perturbation mapping. Chem. Biol. 17, 725–734.
Bollag, D.M., McQueney, P.A., Zhu, J., Hensens, O., Koupal, L., Liesch, J.,
Goetz, M., Lazarides, E., and Woods, C.M. (1995). Epothilones, a new class
of microtubule-stabilizing agents with a Taxol-like mechanism of action.
Cancer Res. 55, 2325–2333.
Brunden, K.R., Trojanowski, J.Q., and Lee, V.M.Y. (2009). Advances in tau-
focused drug discovery for Alzheimer’s disease and related tauopathies.
Nat. Rev. Drug Discov. 8, 783–793.
Buey, R.M., Barasoain, I., Jackson, E., Meyer, A., Giannakakou, P., Paterson,
I., Mooberry, S., Andreu, J.M., and Dı´az, J.F. (2005). Microtubule interactions
with chemically diverse stabilizing agents: thermodynamics of binding to the
paclitaxel site predicts cytotoxicity. Chem. Biol. 12, 1269–1279.
Buey, R.M., Dı´az, J.F., and Andreu, J.M. (2006). The nucleotide switch of
tubulin and microtubule assembly: a polymerization-driven structural change.
Biochemistry 45, 5933–5938.
Buey, R.M., Calvo, E., Barasoain, I., Pineda, O., Edler, M.C., Matesanz, R.,
Cerezo, G., Vanderwal, C.D., Day, B.W., Sorensen, E.J., et al. (2007). Cyclo-
streptin binds covalently to microtubule pores and lumenal taxoid binding
sites. Nat. Chem. Biol. 3, 117–125.
Burkhart, C.A., Kavallaris, M., and Band Horwitz, S. (2001). The role of
b-tubulin isotypes in resistance to antimitotic drugs. Biochim. Biophys. Acta
1471, O1–O9.
Calvo, E., Barasoain, I., Matesanz, R., Pera, B., Camafeita, E., Pineda, O.,
Hamel, E., Vanderwal, C.D., Andreu, J.M., Lo´pez, J.A., and Dı´az, J.F. (2012).
Cyclostreptin derivatives specifically target cellular tubulin and further map
the paclitaxel site. Biochemistry 51, 329–341.
Canales, A., Matesanz, R., Gardner, N.M., Andreu, J.M., Paterson, I., Dı´az,
J.F., and Jime´nez-Barbero, J. (2008). The bound conformation of
microtubule-stabilizing agents: NMR insights into the bioactive 3D structure
of discodermolide and dictyostatin. Chemistry 14, 7557–7569.
Canales, A., Rodrı´guez-Salarichs, J., Trigili, C., Nieto, L., Coderch, C., Andreu,
J.M., Paterson, I., Jime´nez-Barbero, J., and Dı´az, J.F. (2011). Insights into the
interaction of discodermolide and docetaxel with tubulin. Mapping the bindinglogy 20, March 21, 2013 ª2013 Elsevier Ltd All rights reserved 313
Chemistry & Biology
Reviewsites of microtubule-stabilizing agents by using an integrated NMR and
computational approach. ACS Chem. Biol. 6, 789–799.
Carlomagno, T., Blommers, M.J.J., Meiler, J., Jahnke, W., Schupp, T.,
Petersen, F., Schinzer, D., Altmann, K.H., and Griesinger, C. (2003). The
high-resolution solution structure of epothilone A bound to tubulin: an under-
standing of the structure-activity relationships for a powerful class of antitumor
agents. Angew. Chem. Int. Ed. Engl. 42, 2511–2515.
Chen, K., Huzil, J.T., Freedman, H., Ramachandran, P., Antoniou, A.,
Tuszynski, J.A., and Kurgan, L. (2008). Identification of tubulin drug binding
sites and prediction of relative differences in binding affinities to tubulin
isotypes using digital signal processing. J. Mol. Graph. Model. 27, 497–505.
Crume, K.P., O’Sullivan, D., Miller, J.H., Northcote, P.T., and La Flamme, A.C.
(2009). Delaying the onset of experimental autoimmune encephalomyelitis
with the microtubule-stabilizing compounds, paclitaxel and peloruside A. J.
Leuk. Biol. 86, 949–958.
Dı´az, J.F., and Andreu, J.M. (1993). Assembly of purified GDP-tubulin into
microtubules induced by Taxol and Taxotere: reversibility, ligand stoichi-
ometry, and competition. Biochemistry 32, 2747–2755.
Dı´az, J.F., Mene´ndez,M., and Andreu, J.M. (1993). Thermodynamics of ligand-
induced assembly of tubulin. Biochemistry 32, 10067–10077.
Dı´az, J.F., Valpuesta, J.M., Chaco´n, P., Diakun, G., and Andreu, J.M. (1998).
Changes in microtubule protofilament number induced by Taxol binding to
an easily accessible site. Internal microtubule dynamics. J. Biol. Chem. 273,
33803–33810.
Dı´az, J.F., Strobe, R., Engelborghs, Y., Souto, A.A., and Andreu, J.M. (2000).
Molecular recognition of Taxol by microtubules. Kinetics and thermodynamics
of binding of fluorescent Taxol derivatives to an exposed site. J. Biol. Chem.
275, 26265–26276.
Dı´az, J.F., Barasoain, I., and Andreu, J.M. (2003). Fast kinetics of Taxol binding
to microtubules. Effects of solution variables and microtubule-associated
proteins. J. Biol. Chem. 278, 8407–8419.
Dı´az, J.F., Barasoain, I., Souto, A.A., Amat-Guerri, F., and Andreu, J.M. (2005).
Macromolecular accessibility of fluorescent taxoids bound at a paclitaxel
binding site in the microtubule surface. J. Biol. Chem. 280, 3928–3937.
Dı´az, J.F., Andreu, J.M., and Jime´nez-Barbero, J. (2009). The interaction of
microtubules with stabilizers characterized at biochemical and structural
levels. Top. Curr. Chem. 286, 121–149.
Dumontet, C., and Jordan,M.A. (2010).Microtubule-binding agents: a dynamic
field of cancer therapeutics. Nat. Rev. Drug Discov. 9, 790–803.
Dye, R.B., Fink, S.P., and Williams, R.C., Jr. (1993). Taxol-induced flexibility
of microtubules and its reversal by MAP-2 and Tau. J. Biol. Chem. 268,
6847–6850.
Elie-Caille, C., Severin, F., Helenius, J., Howard, J., Muller, D.J., and Hyman,
A.A. (2007). Straight GDP-tubulin protofilaments form in the presence of Taxol.
Curr. Biol. 17, 1765–1770.
Evangelio, J.A., Abal, M., Barasoain, I., Souto, A.A., Lillo, M.P., Acun˜a, A.U.,
Amat-Guerri, F., and Andreu, J.M. (1998). Fluorescent taxoids as probes of
the microtubule cytoskeleton. Cell Motil. Cytoskeleton 39, 73–90.
Field, J.J., Pera, B., Calvo, E., Canales, A., Zurwerra, D., Trigili, C., Rodrı´guez-
Salarichs, J., Matesanz, R., Kanakkanthara, A., Wakefield, S.J., et al. (2012).
Zampanolide, a potent new microtubule-stabilizing agent, covalently reacts
with the taxane luminal site in tubulin a,b-heterodimers and microtubules.
Chem. Biol. 19, 686–698.
Fourniol, F.J., Sindelar, C.V., Amigues, B., Clare, D.K., Thomas, G., Perderiset,
M., Francis, F., Houdusse, A., and Moores, C.A. (2010). Template-free
13-protofilament microtubule-MAP assembly visualized at 8 A resolution. J.
Cell Biol. 191, 463–470.
Freedman, H., Huzil, J.T., Luchko, T., Luduen˜a, R.F., and Tuszynski, J.A.
(2009). Identification and characterization of an intermediate Taxol binding
site withinmicrotubule nanopores and amechanism for tubulin isotype binding
selectivity. J. Chem. Inf. Model. 49, 424–436.
Gaitanos, T.N., Buey, R.M., Dı´az, J.F., Northcote, P.T., Teesdale-Spittle, P.,
Andreu, J.M., and Miller, J.H. (2004). Peloruside A does not bind to the taxoid
site on b-tubulin and retains its activity in multidrug-resistant cell lines. Cancer
Res. 64, 5063–5067.314 Chemistry & Biology 20, March 21, 2013 ª2013 Elsevier Ltd All rGalsky, M.D., Dritselis, A., Kirkpatrick, P., and Oh, W.K. (2010). Cabazitaxel.
Nat. Rev. Drug Discov. 9, 677–678.
Giannakakou, P., Sackett, D.L., Kang, Y.K., Zhan, Z.R., Buters, J.T.M., Fojo,
T., and Poruchynsky, M.S. (1997). Paclitaxel-resistant human ovarian cancer
cells have mutant b-tubulins that exhibit impaired paclitaxel-driven polymeri-
zation. J. Biol. Chem. 272, 17118–17125.
Giannakakou, P., Gussio, R., Nogales, E., Downing, K.H., Zaharevitz, D.,
Bollbuck, B., Poy, G., Sackett, D., Nicolaou, K.C., and Fojo, T. (2000). A
common pharmacophore for epothilone and taxanes: molecular basis for
drug resistance conferred by tubulin mutations in human cancer cells. Proc.
Natl. Acad. Sci. USA 97, 2904–2909.
Gigant, B., Curmi, P.A., Martin-Barbey, C., Charbaut, E., Lachkar, S., Lebeau,
L., Siavoshian, S., Sobel, A., and Knossow, M. (2000). The 4 A X-ray structure
of a tubulin:stathmin-like domain complex. Cell 102, 809–816.
Gonzalez-Garay, M.L., Chang, L., Blade, K., Menick, D.R., and Cabral, F.
(1999). A b-tubulin leucine cluster involved in microtubule assembly and
paclitaxel resistance. J. Biol. Chem. 274, 23875–23882.
Hara, T., Ushio, K., Nishiwaki, M., Kouno, J., Araki, H., Hikichi, Y., Hattori, M.,
Imai, Y., and Yamaoka, M. (2010). A mutation in b-tubulin and a sustained
dependence on androgen receptor signalling in a newly established doce-
taxel-resistant prostate cancer cell line. Cell Biol. Int. 34, 177–184.
Hari, M., Loganzo, F., Annable, T., Tan, X.Z., Musto, S., Morilla, D.B., Nettles,
J.H., Snyder, J.P., and Greenberger, L.M. (2006). Paclitaxel-resistant cells
have a mutation in the paclitaxel-binding region of b-tubulin (Asp26Glu) and
less stable microtubules. Mol. Cancer Ther. 5, 270–278.
He, L.F., Yang, C.P.H., and Horwitz, S.B. (2001). Mutations in b-tubulin map to
domains involved in regulation of microtubule stability in epothilone-resistant
cell lines. Mol. Cancer Ther. 1, 3–10.
Hung, D.T., Chen, J., and Schreiber, S.L. (1996). (+)-Discodermolide binds to
microtubules in stoichiometric ratio to tubulin dimers, blocks Taxol binding and
results in mitotic arrest. Chem. Biol. 3, 287–293.
Huzil, J.T., Chik, J.K., Slysz, G.W., Freedman, H., Tuszynski, J., Taylor, R.E.,
Sackett, D.L., and Schriemer, D.C. (2008). A unique mode of microtubule
stabilization induced by peloruside A. J. Mol. Biol. 378, 1016–1030.
Jime´nez-Barbero, J., Canales, A., Northcote, P.T., Buey, R.M., Andreu, J.M.,
and Dı´az, J.F. (2006). NMR determination of the bioactive conformation
of peloruside A bound to microtubules. J. Am. Chem. Soc. 128, 8757–8765.
Jordan, M.A., and Wilson, L. (2004). Microtubules as a target for anticancer
drugs. Nat. Rev. Cancer 4, 253–265.
Kanakkanthara, A., Wilmes, A., O’Brate, A., Escuin, D., Chan, A., Gjyrezi, A.,
Crawford, J., Rawson, P., Kivell, B., Northcote, P.T., et al. (2011). Peloruside-
and laulimalide-resistant human ovarian carcinoma cells have bI-tubulin
mutations and altered expression of bII- and bIII-tubulin isotypes. Mol. Cancer
Ther. 10, 1419–1429.
Khrapunovich-Baine, M., Menon, V., Verdier-Pinard, P., Smith, A.B., 3rd,
Angeletti, R.H., Fiser, A., Horwitz, S.B., and Xiao, H. (2009). Distinct pose of
discodermolide in taxol binding pocket drives a complementary mode of
microtubule stabilization. Biochemistry 48, 11664–11677.
Khrapunovich-Baine, M., Menon, V., Yang, C.P.H., Northcote, P.T., Miller,
J.H., Angeletti, R.H., Fiser, A., Horwitz, S.B., and Xiao, H. (2011). Hallmarks
of molecular action of microtubule stabilizing agents: effects of epothilone B,
ixabepilone, peloruside A, and laulimalide on microtubule conformation. J.
Biol. Chem. 286, 11765–11778.
Kowalski, R.J., Giannakakou, P., Gunasekera, S.P., Longley, R.E., Day, B.W.,
and Hamel, E. (1997). The microtubule-stabilizing agent discodermolide
competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers,
enhances tubulin nucleation reactions more potently than paclitaxel, and
inhibits the growth of paclitaxel-resistant cells. Mol. Pharmacol. 52, 613–622.
Li, H.L., DeRosier, D.J., Nicholson, W.V., Nogales, E., and Downing, K.H.
(2002). Microtubule structure at 8 A resolution. Structure 10, 1317–1328.
Liu, J.K., Towle, M.J., Cheng, H.S., Saxton, P., Reardon, C., Wu, J.Y., Murphy,
E.A., Kuznetsov, G., Johannes, C.W., Tremblay, M.R., et al. (2007). In vitro and
in vivo anticancer activities of synthetic (-)-laulimalide, a marine natural
product microtubule stabilizing agent. Anticancer Res. 27(3B), 1509–1518.ights reserved
Chemistry & Biology
ReviewLo¨we, J., Li, H., Downing, K.H., and Nogales, E. (2001). Refined structure of
a b-tubulin at 3.5 A resolution. J. Mol. Biol. 313, 1045–1057.
Magnani, M., Maccari, G., Andreu, J.M., Dı´az, J.F., and Botta, M. (2009).
Possible binding site for paclitaxel at microtubule pores. FEBS J. 276,
2701–2712.
Manzo, E., van Soest, R., Matainaho, L., Roberge, M., and Andersen, R.J.
(2003). Ceratamines A and B, antimitotic heterocyclic alkaloids isolated from
the marine sponge Pseudoceratina sp. collected in Papua New Guinea. Org.
Lett. 5, 4591–4594.
Martello, L.A., McDaid, H.M., Regl, D.L., Yang, C.P.H., Meng, D.F., Pettus,
T.R.R., Kaufman, M.D., Arimoto, H., Danishefsky, S.J., Smith, A.B., 3rd, and
Horwitz, S.B. (2000). Taxol and discodermolide represent a synergistic drug
combination in human carcinoma cell lines. Clin. Cancer Res. 6, 1978–1987.
Matesanz, R., Rodrı´guez-Salarichs, J., Pera, B., Canales, A., Andreu, J.M.,
Jime´nez-Barbero, J., Bras, W., Nogales, A., Fang, W.S., and Dı´az, J.F.
(2011). Modulation of microtubule interprotofilament interactions by modified
taxanes. Biophys. J. 101, 2970–2980.
Meyer, C., Ferguson, D., Krauth, M., Wick, M., and Northcote, P. (2006). RTA
301 (peloruside): a novel microtubule stabilizer with potent in vivo activity
against lung cancer and resistant breast cancer. Eur. J. Cancer 4(Suppl ),
192–193.
Mitra, A., and Sept, D. (2008). Taxol allosterically alters the dynamics of the
tubulin dimer and increases the flexibility of microtubules. Biophys. J. 95,
3252–3258.
Moores, C.A., Perderiset, M., Francis, F., Chelly, J., Houdusse, A., and
Milligan, R.A. (2004). Mechanism of microtubule stabilization by doublecortin.
Mol. Cell 14, 833–839.
Nawrotek, A., Knossow, M., and Gigant, B. (2011). The determinants that
govern microtubule assembly from the atomic structure of GTP-tubulin. J.
Mol. Biol. 412, 35–42.
Nettles, J.H., Li, H.L., Cornett, B., Krahn, J.M., Snyder, J.P., and Downing, K.H.
(2004). The binding mode of epothilone A on a,b-tubulin by electron crystallog-
raphy. Science 305, 866–869.
Nguyen, T.L., Xu, X.M., Gussio, R., Ghosh, A.K., and Hamel, E. (2010). The
assembly-inducing laulimalide/peloruside A binding site on tubulin: Molecular
modeling and biochemical studies with [3H]peloruside A. J. Chem. Inf. Model.
50, 2019–2028.
Nogales, E. (2000). Structural insights into microtubule function. Annu. Rev.
Biochem. 69, 277–302.
Nogales, E., Wolf, S.G., Khan, I.A., Luduen˜a, R.F., and Downing, K.H. (1995).
Structure of tubulin at 6.5 A and location of the taxol-binding site. Nature
375, 424–427.
Nogales, E., Wolf, S.G., and Downing, K.H. (1998). Structure of the a b tubulin
dimer by electron crystallography. Nature 391, 199–203.
Nogales, E., Whittaker, M., Milligan, R.A., and Downing, K.H. (1999). High-
resolution model of the microtubule. Cell 96, 79–88.
Nogales, E., Wang, H.W., and Niederstrasser, H. (2003). Tubulin rings: which
way do they curve? Curr. Opin. Struct. Biol. 13, 256–261.
Parness, J., and Horwitz, S.B. (1981). Taxol binds to polymerized tubulin
in vitro. J. Cell Biol. 91, 479–487.
Pera, B., Razzak, M., Trigili, C., Pineda, O., Canales, A., Buey, R.M., Jime´nez-
Barbero, J., Northcote, P.T., Paterson, I., Barasoain, I., and Dı´az, J.F. (2010).
Molecular recognition of peloruside A by microtubules. The C24 primary
alcohol is essential for biological activity. ChemBioChem 11, 1669–1678.
Pineda, O., Farra`s, J., Maccari, L., Manetti, F., Botta, M., and Vilarrasa, J.
(2004). Computational comparison of microtubule-stabilising agents laulima-
lide and peloruside with taxol and colchicine. Bioorg. Med. Chem. Lett. 14,
4825–4829.
Prota, A.E., Bargsten, K., Zurwerra, D., Field, J.J., Dı´az, J.F., Altmann, K.-H.,
and Steinmetz, M.O. (2013). Molecular mechanism of action of microtubule-
stabilizing anticancer agents. Science 339, 587–590.Chemistry & BioPrussia, A.J., Yang, Y.T., Geballe, M.T., and Snyder, J.P. (2010). Cyclostreptin
and microtubules: is a low-affinity binding site required? ChemBioChem 11,
101–109.
Pryor, D.E., O’Brate, A., Bilcer, G., Dı´az, J.F., Wang, Y.F., Wang, Y., Kabaki,
M., Jung, M.K., Andreu, J.M., Ghosh, A.K., et al. (2002). Themicrotubule stabi-
lizing agent laulimalide does not bind in the taxoid site, kills cells resistant to
paclitaxel and epothilones, and may not require its epoxide moiety for activity.
Biochemistry 41, 9109–9115.
Rao, S., Horwitz, S.B., and Ringel, I. (1992). Direct photoaffinity labeling of
tubulin with taxol. J. Natl. Cancer Inst. 84, 785–788.
Rao, S., Krauss, N.E., Heerding, J.M., Swindell, C.S., Ringel, I., Orr, G.A., and
Horwitz, S.B. (1994). 30-(p-azidobenzamido)taxol photolabels the N-terminal
31 amino acids of b-tubulin. J. Biol. Chem. 269, 3132–3134.
Rao, S., Orr, G.A., Chaudhary, A.G., Kingston, D.G.I., and Horwitz, S.B. (1995).
Characterization of the taxol binding site on the microtubule. 2-(m-
Azidobenzoyl)taxol photolabels a peptide (amino acids 217-231) of b-tubulin.
J. Biol. Chem. 270, 20235–20238.
Rao, S., He, L.F., Chakravarty, S., Ojima, I., Orr, G.A., and Horwitz, S.B. (1999).
Characterization of the Taxol binding site on the microtubule. Identification of
Arg(282) in b-tubulin as the site of photoincorporation of a 7-benzophenone
analogue of Taxol. J. Biol. Chem. 274, 37990–37994.
Reese,M., Sa´nchez-Pedregal, V.M., Kubicek, K., Meiler, J., Blommers, M.J.J.,
Griesinger, C., and Carlomagno, T. (2007). Structural basis of the activity of the
microtubule-stabilizing agent epothilone a studied by NMR spectroscopy in
solution. Angew. Chem. Int. Ed. Engl. 46, 1864–1868.
Sa´nchez-Pedregal, V.M., Kubicek, K., Meiler, J., Lyothier, I., Paterson, I., and
Carlomagno, T. (2006). The tubulin-bound conformation of discodermolide
derived by NMR studies in solution supports a common pharmacophore
model for epothilone and discodermolide. Angew. Chem. Int. Ed. Engl. 45,
7388–7394.
Schiff, P.B., Fant, J., and Horwitz, S.B. (1979). Promotion of microtubule
assembly in vitro by taxol. Nature 277, 665–667.
Skoufias, D.A., and Wilson, L. (1992). Mechanism of inhibition of microtubule
polymerization by colchicine: inhibitory potencies of unliganded colchicine
and tubulin-colchicine complexes. Biochemistry 31, 738–746.
Snyder, J.P., Nettles, J.H., Cornett, B., Downing, K.H., and Nogales, E. (2001).
The binding conformation of Taxol in b-tubulin: a model based on electron
crystallographic density. Proc. Natl. Acad. Sci. USA 98, 5312–5316.
Sui, H.X., and Downing, K.H. (2010). Structural basis of interprotofilament
interaction and lateral deformation of microtubules. Structure 18, 1022–1031.
Thepchatri, P., Cicero, D.O., Monteagudo, E., Ghosh, A.K., Cornett, B.,
Weeks, E.R., and Snyder, J.P. (2005). Conformations of laulimalide in
DMSO-d6. J. Am. Chem. Soc. 127, 12838–12846.
Verrills, N.M., Flemming, C.L., Liu, M., Ivery, M.T., Cobon, G.S., Norris, M.D.,
Haber, M., and Kavallaris, M. (2003). Microtubule alterations and mutations
induced by desoxyepothilone B: implications for drug-target interactions.
Chem. Biol. 10, 597–607.
Wyman, J., and Gill, S.J. (1990). Binding and Linkage: Functional Chemistry of
Biological Molecules (Mill Valley, CA: University Science Books).
Xia, S.J., Kenesky, C.S., Rucker, P.V., Smith, A.B., 3rd, Orr, G.A., and Horwitz,
S.B. (2006). A photoaffinity analogue of discodermolide specifically labels
a peptide in b-tubulin. Biochemistry 45, 11762–11775.
Yang, C.P.H., Verdier-Pinard, P., Wang, F., Lippaine-Horvath, E., He, L.F., Li,
D.S., Ho¨fle, G., Ojima, I., Orr, G.A., and Horwitz, S.B. (2005). A highly epothi-
lone B-resistant A549 cell line withmutations in tubulin that confer drug depen-
dence. Mol. Cancer Ther. 4, 987–995.
Yin, S.H., Zeng, C.Q., Hari, M., and Cabral, F. (2012). Random mutagenesis
of b-tubulin defines a set of dispersed mutations that confer paclitaxel
resistance. Pharm. Res. 29, 2994–3006.logy 20, March 21, 2013 ª2013 Elsevier Ltd All rights reserved 315
